SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

United States Oil Fund (USO) is trending with extreme volatility as escalating Middle East tensions and threats to global oil supply from the Strait of Hormuz have driven a sharp price surge. However, community sentiment is now divided between those anticipating sustained higher prices and those expecting a rapid pullback following G7 discussions and actions concerning the release of strategic oil reserves.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers is experiencing a massive surge after partnering with Novo Nordisk to offer branded GLP-1 weight-loss medications, ending a significant legal dispute and fueling widespread community discussion about a potential short squeeze and a fundamental shift in the company's growth trajectory.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS Life Sciences is highly active as bullish investors enthusiastically rally around the CEO's recent comments hinting at "curative outcomes" for its lead AML immunotherapy, GPS, driving significant short squeeze speculation and expectations for imminent positive trial readouts.

AN2 Therapeutics, Inc. operates as a global health biopharmaceutical company. The firm focuses on modern biomedical and drug development to provide transformational medicines for patients suffering from infectious diseases. The company was founded by Eric Easom, George Harrison Talbot, Joseph S. Zakrzewski and Michael R.K. Alley and is headquartered in Menlo Park, CA.

AN2 Therapeutics Inc

AN2 Therapeutics is seeing significantly increased trading volume and speculation following a $40 million private placement financing and an analyst upgrade to Outperform with a $5 price target. The community is actively debating the financing's impact and the potential for a short squeeze in this catalyst-driven biotech, while also weighing ongoing pipeline developments.

🔥 COCK Token – The Ultimate Cross-Chain MemeFi Powerhouse 🔥  In just under 20 days, $COCK has smashed expectations, broken ATHs, and built a project that’s shaking up Cardano and the entire crypto space. 🐓 What Makes $COCK Special?      The Name: Love it or hate it, the energy and engagement it generates are undeniable. The nuance in language and wild appeal set us apart.     #MEMEFI Pioneer: We’re not just another meme coin. $COCK is leading a movement by combining DeFi mechanics, game theory, and community engagement into a groundbreaking ecosystem.     COCKARENA: At the core of our ecosystem is the COCKARENA, a PvP HODL game. Players battle it out, and early exit fees fuel redistributions, burns, and the treasury. This ensures price appreciation and long-term sustainability for loyal holders.  🎰 The COCK Casino  Our casino isn’t just fun—it’s a serious revenue stream for the FLOCK.      Games: Bonanza, Crash, Blackjack, and Roulette (coming soon!).     Impact: Over 7,834 ADA in profits generated within days, directly supporting rewards, burns, and reinvestment.  💰 COCK-ARENA Loans  Unlock liquidity without selling your tokens.      Loan Terms: Borrow up to 30% of your holdings while continuing to earn rewards in the arena.     Investor Focus: Perfect for savvy investors staying in the game while tapping into their holdings.  🤝 Our Insane Partnerships  We’re bridging gaps, building alliances, and breaking barriers across the crypto space. Key Partners:      DANZO: Powering #MEMEFI with Arena, Casino, and Loans.     KLENEK: Interactive training room.     HSKN (Charles Hoskilien): Supporting and starting COCKPIN with 115 AIR NODES for DePIN aggregation. Plans to add APEX and Earth Nodes through a crypto company incorporated in Costa Rica.     ELITE CATS / SNEKKIES / HOT / BANK: Rewarding NFT holders with COCK-LOCK tokens and vice versa.     OCKZ: COCKSOCKS, Golden Cock Ticket (1M COCK), airdrop rewards, and whitelist perks for holders of 200 ADA worth of $COCK.     OLI Partnership:         Content Creation: Lux and the team are crafting engaging educational content about memes and MemeFi for OLi's platform.         Strategic Investment: The OLi Community Trust will invest in $COCK, distributing 100% of rewards to $OLI holders.         Community Reach: Over 22,000 learners will discover $COCK through OLi's gamified ecosystem.     Hi-Rez the Rapper: Expanding reach in marketing and entertainment.     KUNO, CALEB, CADEN, FITY, ROVER, WhaleInsider: Influential collaborators driving crypto adoption and growth.     Cardano Girls: Helping us understand and communicate effectively with ADA’s female audience.     WallStreetBets: Breaking barriers and increasing engagement.     Antonio Brown: Endorsing, supporting, and even playing in the casino and arena!     Advisors:         BERIS, HECKTHESNEK, RTB, CRYPTOGENIUS: Trusted names advising and supporting the project.  Future Partnerships:  More collaborations are in the pipeline to continue expanding engagement and bring new eyes to ADA and CNTs. 🔥 Unmatched Results in Just 20 Days      Supply Burned: 1.65%, worth 148K ADA!     Arena Fees Collected: 54M COCK, worth over 500K ADA, fueling rewards, burns, and partnerships.     Staked COCK-LOCK: 11M COCK-LOCK in the liquid staking platform, with more coming.     Casino Revenue: Skyrocketing profits directly rewarding holders and growing the treasury.     Top Blast Contests: Generated over 120K ADA in volume, rewarding participants with over 50K ADA in prizes.  🌍 Our Vision  To be the most decentralized, rewarding, and innovative token on Cardano while fostering cross-chain collaboration and onboarding the masses.      Breaking Barriers: We’re bringing BTC, ETH, SOL, and other chains into the fold.     Community-Driven: Focused on building bridges and showcasing that crypto can be fun, rewarding, and sustainable.     Expansion: This is just the beginning. With more burns, rewards, and partnerships on the way, $COCK is set to redefine what’s possible in the MemeFi space.  💎 Time in the arena &gt; Timing the market. The FLOCK is unstoppable. Let’s keep breaking walls for Cardano and onboard new users as we take $COCK to new heights.

CockCardano

COCK CRYPTO is trending as its Cocky Wings LLC real-world asset business actively generates revenue, which the community is celebrating for fueling token buybacks and robust growth within its Cardano-based ecosystem and staking arena.

The Boeing Co. is an aerospace company, which engages in the manufacture of commercial jetliners and defense, space, and security systems. It operates through the following segments: Commercial Airplanes (BCA), Defense, Space and Security (BDS), and Global Services (BGS). The Commercial Airplanes segment includes the development, production, and market of commercial jet aircraft and provides fleet support services, principally to the commercial airline industry worldwide. The Defense, Space and Security segment refers to the research, development, production and modification of manned and unmanned military aircraft and weapons systems for global strike, including fighter and combat rotorcraft aircraft and missile systems, global mobility, including tanker, rotorcraft and tilt-rotor aircraft, and airborne surveillance and reconnaissance, including command and control, battle management and airborne anti-submarine aircraft. The Global Services segment provides services to commercial and defense customers. The company was founded by William Edward Boeing on July 15, 1916, and is headquartered in Arlington, VA.

Boeing Co.

Boeing Co

Boeing is a battleground stock as the community debates whether concerns over rising fuel costs from the Iran war, potentially delaying airline orders, outweigh the impact of a massive rumored aircraft deal from China and anticipated increases in defense spending.

SSgA Active Trust - State Street SPDR S&P 500 ETF Trust

SPY is seeing a significant intraday rebound, fueled by former President Trump's comments hinting that the Iran conflict "could be over soon," which has triggered a sharp reversal in oil prices and spurred community debate about market manipulation and a massive short squeeze.

ProShares Trust - ProShares UltraShort Bloomberg Crude Oil -2x Shares

ProShares UltraShort Bloomberg Crude Oil

SCO, an inverse crude oil ETF, is trending amidst extreme volatility in oil prices driven by escalating geopolitical tensions in the Middle East and conflicting narratives surrounding the Strait of Hormuz. The community is actively debating if crude oil is overbought and ripe for a substantial pullback, making SCO an attractive yet scrutinized play for a downturn.

Relmada Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in addressing diseases of the central nervous system. It develops esmethadone, an N-methyl-D-aspartate receptor antagonist for the treatment of CNS diseases, and oral agent for depression and other potential indications. The company was founded by Paolo Manfredi on May 31, 2012 and is headquartered in Coral Gables, FL.

Relmada Therapeutics Inc

Relmada Therapeutics is trending following positive 12-month Phase 2 interim data for its bladder cancer candidate NDV-01, which showed a durable 76% complete response rate and reinforced plans for Phase 3 trials. This, combined with an oversubscribed $160 million private placement, is driving significant trading volume and community discussion.

Tilray Brands, Inc. engages as a consumer packaged goods company, which focuses on medical cannabis research and the cultivation, processing, and distribution of cannabis products worldwide. It operates through the followings segments: Cannabis, Distribution, Beverage, and Wellness. The Cannabis segment focuses on cultivation, production, distribution, and sale of both medical and adult-use cannabis products. The Distribution segment is involved in purchase, resale, and distribution of pharmaceutical and wellness products. The Beverage segment refers to the production, marketing, and sale of beverages. The Wellness segment represents the production, marketing, and distribution of hemp-based food and other wellness products. The company was founded on January 24, 2018 and is headquartered in Leamington, Canada.

Tilray Brands Inc

Tilray is driving conversation after acquiring BrewDog's global assets, with some investors applauding the strategic expansion into beverages and future THC-infused products, while others criticize the costly, dilutive move into a declining craft beer market amidst ongoing anticipation for US Schedule III cannabis rescheduling.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Relmada Therapeutics, Xenon Pharmaceuticals, Dianthus Therapeutics And Other Big Stocks Moving Higher On Monday

US stocks tumble as Dow falls 650 points. Relmada Therapeutics stock rises 40.8% on promising cancer treatment data. Hims & Hers and Xenon Pharma jump over 40%.read more...

Why Is Relmada Therapeutics Stock Soaring Monday?

Relmada Therapeutics shares rise on promising interim data from Phase 2 trial of NDV-01 for non-muscle invasive bladder cancer.read more...

<ul class="summary-bullets"><li>The company said that these interim results support advancement into the Phase 3 RESCUE registrational trial program to evaluate NDV-01.</li><li>Relmada also announced that it has entered into a securities purchase agreement for a private investment in public equity financing, with gross proceeds of $160 million expected.</li><li>The company stated that it intends to use the proceeds for working capital and general corporate purposes, including advancing the research and development of its product candidates.</li></ul>Relmada Therapeutics Inc. (RLMD) shares soared more than 66% in Monday’s pre-market trade before paring some of the gains after the company announced an update in the Phase 2 trial of its bladder cancer treatment.Relmada stated that NDV-01 demonstrated a durable 76% complete response (CR) rate at 12 months, with 95% CR rate at any time in high-risk non-muscle invasive bladder cancer (NMIBC).<a href="https://stocktwits.com/symbol/RLMD">Relmada Therapeutics shares</a> were up nearly 38% in Monday’s opening trade. Retail sentiment on Stocktwits around the company trended in the ‘bullish’ territory at the time of writing.<h2 class="st-heading-2">What Do These Findings Signify?</h2>Relmada stated that its Phase 2 trial findings of NVD-01 demonstrated a 12-month CR rate of 80% in the BCG-unresponsive population. The company stated that this is one of the most difficult-to-treat segments of NMIBC.“We continue to observe strong responses in patients with BCG-unresponsive disease, with no progression to muscle-invasive disease and no patients requiring radical cystectomy,” said Relmada’s Chief Medical Officer-Oncology, Raj S. Pruthi.The company said that these interim results support advancement into the Phase 3 RESCUE registrational trial program to evaluate NDV-01.<h2 class="st-heading-2">What Is NDV-01?</h2>NDV-01 is a sustained-release, intravesical formulation of gemcitabine and docetaxel (Gem/Doce) being developed to treat non-muscle invasive bladder cancer. It is designed to retain the drugs in the bladder and release them gradually over a 10-day period.NDV-01 comes ready to use and can be administered in about five minutes without anesthesia or specialized equipment. It is protected by patents through 2038.The company highlighted three upcoming milestones of NDV-01. It expects clearance for its Investigational New Drug (IND) application and the initiation of its Phase 3 RESCUE Program by mid-2026. The initial 3-month results from its Phase 3 2L BCG-unresponsive study are expected by the end of the year.<h2 class="st-heading-2">Relmada Announces $160 Million Financing</h2>Relmada also announced that it has entered into a securities purchase agreement for a private investment in public equity (PIPE) financing, expecting gross proceeds of $160 million.The company stated that it intends to use the proceeds for working capital and general corporate purposes, including advancing the research and development of its product candidates.<a href="https://stocktwits.com/symbol/RLMD">RLMD stock</a> is up 24% year-to-date and 1,987% over the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/iran-ceasefire-discussions-irrelevant-us-israel-want-to-fragment-country/cZdVSRXRIIX">Iran Says Ceasefire Discussions 'Irrelevant', Warns US And Israel Want To Fragment The Country: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

RLMD Stock Soars Pre-Market: Phase 2 Bladder Cancer Trial Data Impresses Investors

Relmada stated that the therapy showed a 76% complete response rate at 12 months in high-risk non-muscle invasive bladder cancer.

Equity

Psychedelic Medicine Advances: Here Are Five Companies Targeting CNS Disorders

Psychedelic Medicine Advances: Here Are Five Companies Targeting CNS Disorders Psychedelic Medicine Advances: Here Are Five Companies Targeting CNS Disorders PR Newswire VANCOUVER, BC, Feb. 26, 2026...

Relmada Therapeutics, Inc. (NASDAQ:RLMD) Receives Consensus Rating of "Hold" from Analysts

Shares of Relmada Therapeutics, Inc. (NASDAQ:RLMD - Get Free Report) have been given an average recommendation of "Hold" by the five research firms that are covering the company, Marketbeat.com...

Relmada Therapeutics (NASDAQ:RLMD) Trading Up 6.9% - Here's Why

Relmada Therapeutics (NASDAQ:RLMD) Trading Up 6.9% - Should You Buy...

Relmada Therapeutics, Inc. (NASDAQ:RLMD) Given Average Rating of "Hold" by Analysts

Relmada Therapeutics, Inc. (NASDAQ:RLMD - Get Free Report) has been assigned an average rating of "Hold" from the five analysts that are presently covering the stock, MarketBeat reports. One...

Relmada Therapeutics (NASDAQ:RLMD) Upgraded by Leerink Partners to Outperform Rating

Leerink Partners upgraded Relmada Therapeutics from a "market perform" rating to an "outperform" rating and set a $8.00 price target on the stock in a report on Friday...

Relmada Therapeutics, Inc. (NASDAQ:RLMD) Short Interest Update

Relmada Therapeutics, Inc. (NASDAQ:RLMD - Get Free Report) was the recipient of a significant growth in short interest in December. As of December 15th, there was short interest totaling 980,736...

Relmada Therapeutics (NASDAQ:RLMD) Stock Rating Upgraded by Jefferies Financial Group

Jefferies Financial Group raised Relmada Therapeutics to a "strong-buy" rating in a report on Monday...

Iran / Geopolitical tensions

Fed speakers

Macro data

Earnings

What will be the primary market driver this week?

Stocktwits

Stocktwits Polls

Traders are hyped by positive Phase 2 bladder cancer data, showing a 76% response rate, and an oversubscribed $160M private placement to advance trials.

The stock is experiencing massive premarket and intraday gains, often jumping 30-50% on exceptional volume, with many speculating a push past $7 towards $8-$14 targets.

Discussions center on a potential short squeeze, citing scarcity of short shares and algorithms triggering covers around key price levels like $6.35-$6.75.

Traders are keenly analyzing chart patterns like "cup and handle," watching for bounces off dips, and identifying critical resistance levels for scalp plays and entries.

Despite positive news, some users express concerns about potential share dilution following the $160M private placement and its impact on price.

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	-$0.15	--	--	N/A
Q3 '25	-$0.42	-$0.30	29.28%	BEAT
Q2 '25	-$0.46	-$0.30	34.78%	BEAT
Q1 '25	-$0.48	-$0.58	-20.83%	MISSED
Q4 '24	-$0.71	-$0.62	12.26%	BEAT

RLMD
Relmada Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q4 '25

Historical Earnings

Latest RLMD News

RLMDRelmada Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Historical Earnings

Latest RLMD News

RLMD
Relmada Therapeutics Inc